Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double‐blind placebo‐controlled clinical trial

Citations Over TimeTop 10% of 2016 papers

Abstract

The effects of allergen immunotherapy (AIT) on local allergic rhinitis (LAR) are largely unknown. We conducted the first randomized, double-blind, placebo-controlled (DBPC), phase II trial of D. pteronyssinus (DP) subcutaneous AIT (DP-AIT) on LAR (clinicaltrials.gov identifier: NCT02123316). Thirty-six LAR patients received Pangramin PLUS DP or placebo for 24 months. The primary endpoints were symptoms, medication scores, and medication-free days. The secondary included skin test, serum specific IgE and IgG4, nasal allergen provocation test (NAPT), and adverse events. AIT-DP produced significant improvements in both primary and secondary endpoints vs placebo. After 12 months of AIT-DP, we detected a significant and marked increase in allergen tolerance with negative NAPT in 50% of patients, and significant increases of serum sIgG4. Immunotherapy was well tolerated; no systemic reactions were reported. This study demonstrated that AIT-DP is a safe and clinically effective treatment for LAR, confirming that LAR is a new indication for AIT.

Related Papers

• Nasal provocation test in the diagnostics of occupational allergic rhinitis.(1996)
• → The Effect of the Nasal Cycle on the Interpretation of Rhinomanometric Results in a Nasal Provocation Test(1990)9 cited
• → Influence of sensitization and allergen provocation procedures on the development of allergen‐induced bronchial hyperreactivity in conscious, unrestrained guinea‐pigs(1995)2 cited
• [Nasal provocation tests in the diagnosis of allergic rhinitis].(2006)
• Nasal allergen provocation test in nasal polyposis with and without allergy(2013)